Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $69.89, with a ...

Needham analyst Joseph Stringer maintained a Buy rating on Phathom Pharmaceuticals (PHAT – Research Report) today and set a price target of ...

We recently published a list of 10 Worst High-Risk High-Reward Growth Stocks To Buy. In this article, we are going to take a ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on PTC Therapeutics (PTCT – Research Report) and ...

Rhythm Pharmaceuticals had a negative net margin of 230.07% and a negative return on equity of 367.36%. The company had revenue of $41.83 million for the quarter, compared to the consensus ...

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced ...

New registry study to focus on impact of fatigue in people with craniopharyngiomaBOSTON, March 18, 2025 (GLOBE NEWSWIRE) -- ...

Rhythm Pharmaceuticals (NASDAQ:RYTM – Free Report) had its target price increased by Needham & Company LLC from $64.00 to $66.00 in a research note released on Tuesday, Marketbeat reports. Needham & ...

Detailed price information for Soleno Therapeutics Inc (SLNO-Q) from The Globe and Mail including charting and trades.

10 analysts have shared their evaluations of Rhythm Pharmaceuticals (NASDAQ:RYTM) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a ...

Rhythm Pharmaceuticals, Inc. has announced a collaboration with the Raymond A. Wood Foundation to conduct research on the impact of fatigue in individuals diagnosed with craniopharyngioma ...